# A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct06492005/  
OnCo record `nct06492005` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of 9MW2821 in triple-negative breast cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.

## Summary

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer is a phase 2 interventional study registered as NCT06492005 by Mabwell (Shanghai) Bioscience Co., Ltd., with 160 participants planned, started 2024-07-26 and due to reach its primary completion in 2026-07. Interventions recorded: 9MW2821 and PD-1 inhibitior.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06492005
- Phase: 2
- Setting: A Phase II Clinical Study of Efficacy and Safety of 9MW2821Monotherapy or Combined With PD-1 Inhibitor in Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT06492005: https://clinicaltrials.gov/study/NCT06492005

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)

---
JSON: https://onco.cc/api/v1/entities/nct06492005.json